Patient Perspectives on Psoriasis Management: U.S. Results of the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

Background Psoriasis and psoriatic arthritis are associated with a high disease burden, underdiagnosis, and undertreatment. Objective To further understand unmet needs in patients with psoriasis and psoriatic arthritis. Methods The population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey included psoriasis and/or psoriatic arthritis patients selected by list-assisted random digit dialing. We report results from the United States. Results 52,926 households in the United States were screened; 1,005 adults completed the survey. Of these, 73.1% of patients reported a psoriasis diagnosis alone and 26.9% reported psoriatic arthritis (with/without a separate psoriasis diagnosis). Approximately 22% of patients reported no current treatment; <10% of psoriasis and 50% of psoriatic arthritis patients were receiving systemic therapy. Perceived treatment burden, safety and tolerability concerns, and lack of effectiveness were commonly reported as reasons for treatment dissatisfaction and discontinuation. Conclusions Psoriasis and psoriatic arthritis remain undertreated in the United States, marked by high treatment dissatisfaction and discontinuation.